Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME).

被引：0
|
作者：
Vermorken, J. B.
Mesia, R.
Vega-Villegas, M. E.
Remenar, E.
Hitt, R.
Kawecki, A.
Rottey, S.
Zabolotnyy, D.
Erfan, J.
Amellal, N.
Antwerpen, U. Z.
机构：
[1] UZ Antwerpen, Edegem, Belgium
[2] Hosp Duran I Reynals Inst Catala Oncol, Barcelona, Spain
[3] Hosp Univ Marques Valdecilla, Santander, Spain
[4] Orszagos Onkol Intezet, Budapest, Hungary
[5] Hosp 12 Octubre, E-28041 Madrid, Spain
[6] Klin Nowotworow Glowy & Szyi, Warsaw, Poland
[7] UZ Gent, Ghent, Belgium
[8] Inst Otolaringol AMS Ukraine, Kiev, Ukraine
[9] Szalbolcs Szatmar Bereg Megyei Josa Andras Korhaz, Nyiregyhaza, Hungary
[10] Merck KGaA, Darmstadt, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：289S / 289S
页数：1
相关论文
共 50 条
  • [41] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03.
    Guigay, Joel
    Fayette, Jerome
    Dillies, Anne-Francoise
    Sire, Christian
    Kerger, Joseph N.
    Tennevet, Isabelle
    Machiels, Jean-Pascal H.
    Zanetta, Sylvie
    Pointreau, Yoann
    Le Moal, Laurence Bozec
    Ribere, Lydia Brugel
    Henry, Stefanie
    Temam, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Cetuximab 1 platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE)
    Le Tourneau, C.
    Ghiani, M.
    Cau, M. C.
    Depenni, R.
    Ronzino, G.
    Bonomo, P.
    Montesarchio, V.
    Leo, L.
    Schulten, J.
    Messinger, D.
    Sbrana, A.
    Ghi, M. G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Hiramoto, Shuji
    Kato, Ken
    Shoji, Hirokazu
    Okita, Natsuko T.
    Takashima, Atsuo
    Honma, Yoshitaka
    Iwasa, Satoru
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [44] Tegafur-Uracil versus 5-Fluorouracil in Combination with Cisplatin and Cetuximab in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Propensity Score Matching Analysis
    Hsieh, Meng-Che
    Wang, Chih-Chun
    Yang, Chuan-Chien
    Lien, Ching-Feng
    Wang, Chien-Chung
    Shih, Yu-Chen
    Yeh, Shyh-An
    Hwang, Tzer-Zen
    BIOLOGY-BASEL, 2021, 10 (10):
  • [45] A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma
    Hiramoto, Shuji
    Kato, Ken
    Shoji, Hirokazu
    Okita, Natsuko
    Takashima, Atsuo
    Honma, Yoshitaka
    Iwasa, Satoru
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    Boku, Narikazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (03) : 466 - 472
  • [46] A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma
    Shuji Hiramoto
    Ken Kato
    Hirokazu Shoji
    Natsuko Okita
    Atsuo Takashima
    Yoshitaka Honma
    Satoru Iwasa
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Narikazu Boku
    International Journal of Clinical Oncology, 2018, 23 : 466 - 472
  • [47] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [48] PEACE trial: A phase 3 trial of paclitaxel, carboplatin and cetuximab vs cisplatin, 5-FU and cetuximab in R/M SCCHN
    Tahara, Makoto
    ANNALS OF ONCOLOGY, 2015, 26 : 14 - 14
  • [49] Phase I-II study with docetaxel (D), cisplatin (C) and 5-fluorouracil (5-FU) in patients (pts) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)
    Schrijvers, D
    Van Herpen, C
    Kerger, J
    Joosens, E
    Le Bouder, C
    Castelijns, J
    Awada, A
    Vermorken, JB
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S164 - S164
  • [50] Cetuximab plus chemoradiation with cisplatin and 5-fluorouracil (5-FU) in locally advanced unresectable esophageal squamous cell carcinoma.
    Sunpaweravong, P.
    Sunpaweravong, S.
    Sangthawan, D.
    Pinaikul, S.
    Attasaranya, S.
    Dechaphunkul, A.
    Mitarnun, W.
    Fungthammasarn, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345